JP2016513458A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513458A5 JP2016513458A5 JP2016501065A JP2016501065A JP2016513458A5 JP 2016513458 A5 JP2016513458 A5 JP 2016513458A5 JP 2016501065 A JP2016501065 A JP 2016501065A JP 2016501065 A JP2016501065 A JP 2016501065A JP 2016513458 A5 JP2016513458 A5 JP 2016513458A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- cancer
- tmz
- tumor
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 25
- 210000004027 cell Anatomy 0.000 claims 19
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 14
- 229960004964 temozolomide Drugs 0.000 claims 14
- 201000011510 cancer Diseases 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- -1 methyl guanine Chemical compound 0.000 claims 7
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 6
- 239000013598 vector Substances 0.000 claims 6
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims 4
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 201000010915 Glioblastoma multiforme Diseases 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 claims 2
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 claims 2
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 108700012439 CA9 Proteins 0.000 claims 2
- 108010058905 CD44v6 antigen Proteins 0.000 claims 2
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 claims 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 claims 2
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims 2
- 102100038083 Endosialin Human genes 0.000 claims 2
- 108010055196 EphA2 Receptor Proteins 0.000 claims 2
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims 2
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims 2
- 102000010451 Folate receptor alpha Human genes 0.000 claims 2
- 108050001931 Folate receptor alpha Proteins 0.000 claims 2
- 101710088083 Glomulin Proteins 0.000 claims 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims 2
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims 2
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims 2
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 claims 2
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 claims 2
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims 2
- 101000910338 Homo sapiens Carbonic anhydrase 9 Proteins 0.000 claims 2
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims 2
- 101000884275 Homo sapiens Endosialin Proteins 0.000 claims 2
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims 2
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 2
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims 2
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims 2
- 101001076732 Homo sapiens RNA-binding protein 27 Proteins 0.000 claims 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 2
- 101000801433 Homo sapiens Trophoblast glycoprotein Proteins 0.000 claims 2
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims 2
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims 2
- 102000004553 Interleukin-11 Receptors Human genes 0.000 claims 2
- 108010017521 Interleukin-11 Receptors Proteins 0.000 claims 2
- 102000007482 Interleukin-13 Receptor alpha2 Subunit Human genes 0.000 claims 2
- 108010085418 Interleukin-13 Receptor alpha2 Subunit Proteins 0.000 claims 2
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 102000003735 Mesothelin Human genes 0.000 claims 2
- 108090000015 Mesothelin Proteins 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims 2
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims 2
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims 2
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims 2
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 102100025873 RNA-binding protein 27 Human genes 0.000 claims 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 2
- 102100033579 Trophoblast glycoprotein Human genes 0.000 claims 2
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims 2
- 108091008605 VEGF receptors Proteins 0.000 claims 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 claims 2
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 2
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 2
- 230000001605 fetal effect Effects 0.000 claims 2
- 238000011331 genomic analysis Methods 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 238000012737 microarray-based gene expression Methods 0.000 claims 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims 2
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims 2
- 101150047061 tag-72 gene Proteins 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Natural products O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims 1
- 241000713666 Lentivirus Species 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- KRWMERLEINMZFT-UHFFFAOYSA-N O6-benzylguanine Chemical compound C=12NC=NC2=NC(N)=NC=1OCC1=CC=CC=C1 KRWMERLEINMZFT-UHFFFAOYSA-N 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 210000002865 immune cell Anatomy 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 238000009169 immunotherapy Methods 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 210000000581 natural killer T-cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 241000701161 unidentified adenovirus Species 0.000 claims 1
- 241001430294 unidentified retrovirus Species 0.000 claims 1
- 239000013603 viral vector Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361775668P | 2013-03-10 | 2013-03-10 | |
| US61/775,668 | 2013-03-10 | ||
| PCT/US2014/022786 WO2014164554A1 (en) | 2013-03-10 | 2014-03-10 | Chemotherapy-resistant immune cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016513458A JP2016513458A (ja) | 2016-05-16 |
| JP2016513458A5 true JP2016513458A5 (enExample) | 2017-04-06 |
Family
ID=50639912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501065A Pending JP2016513458A (ja) | 2013-03-10 | 2014-03-10 | 化学療法耐性免疫細胞 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160024175A1 (enExample) |
| EP (1) | EP2968601A1 (enExample) |
| JP (1) | JP2016513458A (enExample) |
| HK (1) | HK1220614A1 (enExample) |
| WO (1) | WO2014164554A1 (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3970736A1 (en) | 2009-11-02 | 2022-03-23 | Emory University | Drug resistant immunotherapy for treatment of a cancer |
| WO2014117121A1 (en) | 2013-01-28 | 2014-07-31 | St. Jude Children's Research Hospital, Inc. | A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease |
| AU2014265487B2 (en) | 2013-05-14 | 2020-10-22 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
| US9701758B2 (en) | 2013-05-24 | 2017-07-11 | Board Of Regents, The University Of Texas System | Anti-CD19 scFv (FMC63) polypeptide |
| US20160376375A1 (en) * | 2013-11-27 | 2016-12-29 | Baylor College Of Medicine | CSGP4 - Specific Chimeric Antigen Receptor for Cancer |
| ES2764471T3 (es) | 2014-02-14 | 2020-06-03 | Univ Texas | Receptores de antígeno quimérico y procedimientos de fabricación |
| CA2948462A1 (en) | 2014-05-15 | 2015-11-19 | National University Of Singapore | Modified natural killer cells and uses thereof |
| CN107109419B (zh) | 2014-07-21 | 2020-12-22 | 诺华股份有限公司 | 使用cd33嵌合抗原受体治疗癌症 |
| BR112017001183A2 (pt) | 2014-07-21 | 2017-11-28 | Novartis Ag | tratamento de câncer usando receptor de antígeno quimérico anti-bcma humanizado |
| CA2964783C (en) | 2014-11-05 | 2024-01-23 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) to selectively target protein complexes |
| EP3227317A4 (en) * | 2014-12-02 | 2018-04-25 | Roger Williams Hospital | Methods and compositons for treating cancer |
| CA2972806A1 (en) * | 2014-12-31 | 2016-07-07 | Anthrogenesis Corporation | Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells |
| US20160208018A1 (en) | 2015-01-16 | 2016-07-21 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for ror1 |
| US11000548B2 (en) | 2015-02-18 | 2021-05-11 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11304976B2 (en) | 2015-02-18 | 2022-04-19 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017141243A1 (en) | 2016-02-18 | 2017-08-24 | Enlivex Therapeutics Ltd. | Combination immune therapy and cytokine control therapy for cancer treatment |
| KR20170117450A (ko) | 2015-02-18 | 2017-10-23 | 엔리벡스 테라퓨틱스 리미티드 | 암 치료를 위한 면역 요법 및 사이토카인 조절 요법의 조합 |
| WO2016170541A1 (en) | 2015-04-21 | 2016-10-27 | Enlivex Therapeutics Ltd. | Therapeutic pooled blood apoptotic cell preparations and uses thereof |
| US11497767B2 (en) | 2015-02-18 | 2022-11-15 | Enlivex Therapeutics R&D Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| US11596652B2 (en) | 2015-02-18 | 2023-03-07 | Enlivex Therapeutics R&D Ltd | Early apoptotic cells for use in treating sepsis |
| US11318163B2 (en) | 2015-02-18 | 2022-05-03 | Enlivex Therapeutics Ltd | Combination immune therapy and cytokine control therapy for cancer treatment |
| WO2017041106A1 (en) * | 2015-09-03 | 2017-03-09 | The Uab Research Foundation | Genetically-engineered drug resistant t cells and methods of using the same |
| EP4006056A1 (en) | 2016-02-02 | 2022-06-01 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| SG11201901347UA (en) * | 2016-08-18 | 2019-03-28 | Uab Res Found | Compositions and methods for cancer immunotherapy |
| KR102618373B1 (ko) * | 2016-12-09 | 2023-12-29 | 유에이비 리서치 파운데이션 | 키메라성 클로로톡신 수용체 |
| CN110376718A (zh) * | 2016-12-30 | 2019-10-25 | 玉晶光电(厦门)有限公司 | 光学成像镜头 |
| CN117363636A (zh) | 2017-03-27 | 2024-01-09 | 新加坡国立大学 | 一种编码嵌合受体的多核苷酸 |
| CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
| US10561686B2 (en) * | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| US12441787B2 (en) | 2018-04-02 | 2025-10-14 | National University Of Singapore | Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| JP7438988B2 (ja) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | Ｂｃｍａキメラ抗原受容体及びその使用 |
| US12486514B2 (en) | 2018-08-29 | 2025-12-02 | National University Of Singapore | Method to specifically stimulate survival and expansion of genetically-modified immune cells |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| KR20210137085A (ko) | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| MX2024003887A (es) | 2021-10-14 | 2024-07-09 | Arsenal Biosciences Inc | Células inmunitarias que tienen arnch coespresados y sistemas de compuerta lógica. |
| KR20250089492A (ko) * | 2022-11-07 | 2025-06-18 | 네오이뮨텍, 인코퍼레이티드 | 비메틸화된 mgmt 프로모터를 갖는 종양의 치료 방법 |
| AU2024233625A1 (en) | 2023-03-03 | 2025-09-18 | Arsenal Biosciences, Inc. | Systems targeting psma and ca9 |
-
2014
- 2014-03-10 JP JP2016501065A patent/JP2016513458A/ja active Pending
- 2014-03-10 HK HK16108665.9A patent/HK1220614A1/zh unknown
- 2014-03-10 US US14/773,416 patent/US20160024175A1/en not_active Abandoned
- 2014-03-10 EP EP14721581.8A patent/EP2968601A1/en not_active Ceased
- 2014-03-10 WO PCT/US2014/022786 patent/WO2014164554A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016513458A5 (enExample) | ||
| Luo et al. | Progress and prospect of immunotherapy for triple-negative breast cancer | |
| Zhou et al. | Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance | |
| JP6867347B2 (ja) | 免疫療法のためのエンゲージャー細胞 | |
| Li et al. | Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing | |
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| JP2016520302A5 (enExample) | ||
| JP2019517788A5 (enExample) | ||
| Huang et al. | IGF1R-and ROR1-specific CAR T cells as a potential therapy for high risk sarcomas | |
| Helmy et al. | Cancer immunotherapy: accomplishments to date and future promise | |
| Comoli et al. | Development of adaptive immune effector therapies in solid tumors | |
| JP2017503472A5 (enExample) | ||
| JP2015535689A5 (enExample) | ||
| Orentas et al. | Immunotherapy targets in pediatric cancer | |
| IL276554B1 (en) | Non-hla restricted t cell receptors and uses thereof | |
| Guo et al. | Chimeric antigen receptor‐modified T cells for solid tumors: challenges and prospects | |
| JP2021521818A (ja) | 有効な免疫療法のための抗原−サイトカイン複合体に用いた免疫エフェクター細胞及び分子アダプター | |
| JP2019532997A5 (enExample) | ||
| RU2015116901A (ru) | Композиции и способы для имуннотерапии | |
| JP2014512183A5 (enExample) | ||
| JP2020511462A5 (enExample) | ||
| Azadi et al. | Recent advances on immune targeted therapy of colorectal cancer using bi-specific antibodies and therapeutic vaccines | |
| JP2018537536A5 (enExample) | ||
| JP2018526453A5 (enExample) | ||
| Laurent et al. | Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors |